FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109682009> ?p ?o ?g. }

• W2109682009 endingPage "R99" @default.
• W2109682009 startingPage "R99" @default.
• W2109682009 abstract "The purpose of this study was to determine whether anti-tumour necrosis factor alpha (anti-TNF-α) antibody, infliximab, can inhibit T helper 17 (Th17) differentiation in uveitis patients who have Behçet's disease (BD). To measure inflammatory cytokines, ocular fluid samples from BD patients being treated with infliximab were collected. Cluster of differentiation 4 (CD4)+ T cells from BD patients with active uveitis were co-cultured with anti-cluster of differentiation 3/cluster of differentiation 28 (CD3/CD28) antibodies in the presence of infliximab. For the induction of Th17 cells, CD4+ T cells from BD patients were co-cultured with anti-CD3/CD28, anti-interferon-gamma (anti-IFN-γ), anti-interleukin-4 (anti-IL-4), and recombinant proteins such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-23 (IL-23), and TNF-α. The BD T cells were co-cultured with infliximab, and the production of interleukin-17 (IL-17) was evaluated by ELISA and flow cytometry, and the expression of retinoid-acid receptor-related orphan receptor gamma t (RORγt) was also evaluated by flow cytometry. In addition, intraocular cells collected from mice with experimental autoimmune uveitis (EAU) were used for the assay with anti-TNF-α blocking antibody. Ocular fluids from active uveitis patients who have BD contained significant amounts of inflammatory cytokines such as IFN-γ, IL-2, TNF-α, IL-6, and IL-17, while ocular fluids from infliximab patients did not contain any inflammatory cytokines. Activated CD4+ T cells from BD patients produced large amounts of TNF-α and IL-17, whereas T cells in the presence of infliximab failed to produce these cytokines. Polarized Th17 cell lines from BD patients produced large amounts of IL-17, and Th17 cells exposed to infliximab had significantly reduced IL-17 production. Polarized BD Th17 cells expressed large amounts of transcription factor RORγt. In contrast, in vitro-treated infliximab Th17 cells expressed less RORγt. Moreover, intraocular T cells from EAU mice had a high population of IL-17+ cells, and retinal antigen-specific T cells from EAU mice produced large amounts of IL-17 in the presence of retinal peptide. However, the EAU T cells produced less IL-17 if the T cells were treated with anti-TNF-α antibody. These results indicate that anti-TNF-α therapy suppresses effector T-cell differentiation in BD patients with uveitis. Thus, suppression of effector T-cell differentiation by anti-TNF-α therapy may provide protection from severe ocular inflammation in BD." @default.
• W2109682009 created "2016-06-24" @default.
• W2109682009 creator A5007816743 @default.
• W2109682009 creator A5017787125 @default.
• W2109682009 creator A5029122307 @default.
• W2109682009 creator A5035254828 @default.
• W2109682009 creator A5040963064 @default.
• W2109682009 creator A5078503618 @default.
• W2109682009 date "2012-01-01" @default.
• W2109682009 modified "2023-10-18" @default.
• W2109682009 title "Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease" @default.
• W2109682009 cites W1977672535 @default.
• W2109682009 cites W1980888912 @default.
• W2109682009 cites W1981651463 @default.
• W2109682009 cites W1984228289 @default.
• W2109682009 cites W1991528145 @default.
• W2109682009 cites W1991766753 @default.
• W2109682009 cites W2002210913 @default.
• W2109682009 cites W2013517074 @default.
• W2109682009 cites W2019615790 @default.
• W2109682009 cites W2024490058 @default.
• W2109682009 cites W2025813691 @default.
• W2109682009 cites W2026711066 @default.
• W2109682009 cites W2041820432 @default.
• W2109682009 cites W2049056531 @default.
• W2109682009 cites W2061217789 @default.
• W2109682009 cites W2062261063 @default.
• W2109682009 cites W2065059951 @default.
• W2109682009 cites W2065267024 @default.
• W2109682009 cites W2072859659 @default.
• W2109682009 cites W2077352547 @default.
• W2109682009 cites W2078531117 @default.
• W2109682009 cites W2093958012 @default.
• W2109682009 cites W2097057955 @default.
• W2109682009 cites W2111800737 @default.
• W2109682009 cites W2112866067 @default.
• W2109682009 cites W2123249923 @default.
• W2109682009 cites W2126193607 @default.
• W2109682009 cites W2136177420 @default.
• W2109682009 cites W2147171610 @default.
• W2109682009 cites W2155779547 @default.
• W2109682009 cites W2158200396 @default.
• W2109682009 doi "https://doi.org/10.1186/ar3824" @default.
• W2109682009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3446476" @default.
• W2109682009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22546542" @default.
• W2109682009 hasPublicationYear "2012" @default.
• W2109682009 type Work @default.
• W2109682009 sameAs 2109682009 @default.
• W2109682009 citedByCount "106" @default.
• W2109682009 countsByYear W21096820092012 @default.
• W2109682009 countsByYear W21096820092013 @default.
• W2109682009 countsByYear W21096820092014 @default.
• W2109682009 countsByYear W21096820092015 @default.
• W2109682009 countsByYear W21096820092016 @default.
• W2109682009 countsByYear W21096820092017 @default.
• W2109682009 countsByYear W21096820092018 @default.
• W2109682009 countsByYear W21096820092019 @default.
• W2109682009 countsByYear W21096820092020 @default.
• W2109682009 countsByYear W21096820092021 @default.
• W2109682009 countsByYear W21096820092022 @default.
• W2109682009 countsByYear W21096820092023 @default.
• W2109682009 crossrefType "journal-article" @default.
• W2109682009 hasAuthorship W2109682009A5007816743 @default.
• W2109682009 hasAuthorship W2109682009A5017787125 @default.
• W2109682009 hasAuthorship W2109682009A5029122307 @default.
• W2109682009 hasAuthorship W2109682009A5035254828 @default.
• W2109682009 hasAuthorship W2109682009A5040963064 @default.
• W2109682009 hasAuthorship W2109682009A5078503618 @default.
• W2109682009 hasBestOaLocation W21096820091 @default.
• W2109682009 hasConcept C148125776 @default.
• W2109682009 hasConcept C17991360 @default.
• W2109682009 hasConcept C203014093 @default.
• W2109682009 hasConcept C2776090121 @default.
• W2109682009 hasConcept C2776194053 @default.
• W2109682009 hasConcept C2777138892 @default.
• W2109682009 hasConcept C2778690821 @default.
• W2109682009 hasConcept C2779727006 @default.
• W2109682009 hasConcept C2780841837 @default.
• W2109682009 hasConcept C47348012 @default.
• W2109682009 hasConcept C71924100 @default.
• W2109682009 hasConcept C74172505 @default.
• W2109682009 hasConcept C74737994 @default.
• W2109682009 hasConcept C8891405 @default.
• W2109682009 hasConceptScore W2109682009C148125776 @default.
• W2109682009 hasConceptScore W2109682009C17991360 @default.
• W2109682009 hasConceptScore W2109682009C203014093 @default.
• W2109682009 hasConceptScore W2109682009C2776090121 @default.
• W2109682009 hasConceptScore W2109682009C2776194053 @default.
• W2109682009 hasConceptScore W2109682009C2777138892 @default.
• W2109682009 hasConceptScore W2109682009C2778690821 @default.
• W2109682009 hasConceptScore W2109682009C2779727006 @default.
• W2109682009 hasConceptScore W2109682009C2780841837 @default.
• W2109682009 hasConceptScore W2109682009C47348012 @default.
• W2109682009 hasConceptScore W2109682009C71924100 @default.
• W2109682009 hasConceptScore W2109682009C74172505 @default.
• W2109682009 hasConceptScore W2109682009C74737994 @default.
• W2109682009 hasConceptScore W2109682009C8891405 @default.
• W2109682009 hasIssue "3" @default.

• next